Valeant Unloads $2B In Assets To Pay Down Debt
Valeant Pharmaceuticals International Inc. has agreed to sell three skin care brands and a cancer treatment maker in a pair of deals worth $2.12 billion, as the struggling drugmaker looks to...To view the full article, register now.
Already a subscriber? Click here to view full article